Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors
Status:
Active, not recruiting
Trial end date:
2023-12-29
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, phase I study to evaluate the safety and tolerability of
durvalumab ± tremelimumab in combination with chemoradiation in patients with advanced solid
tumors